Zacks Investment Management Jounce Therapeutics, Inc. Transaction History

Zacks Investment Management

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 17, 2021	SELL	$6.73 - $13.87 $1.01 Million - $2.09 Million	-150,542 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$6.37 - $10.33 $105,398 - $170,920	-16,546 Reduced 9.9%	150,542 $1.05 Million
Q3 2020 Nov 16, 2020	SELL	$4.58 - $10.95 $466,669 - $1.12 Million	-101,893 Reduced 37.88%	167,088 $1.36 Million
Q2 2020 Aug 14, 2020	SELL	$4.17 - $7.58 $390,553 - $709,927	-93,658 Reduced 25.83%	268,981 $1.86 Million
Q1 2020 May 15, 2020	BUY	$2.91 - $8.7 $683,276 - $2.04 Million	234,803 Added 183.68%	362,639 $1.72 Million
Q4 2019 Feb 14, 2020	BUY	$2.81 - $9.21 $359,219 - $1.18 Million	127,836 New	127,836 $1.12 Million

720K

Ticker JNCE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,694,200
Description
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid ...

Get notified when there are updates to the investment portfolio of Zacks Investment Management, based on Form 13F filings with the SEC.

Stay updated on Zacks Investment Management with notifications on news.